Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA) has announced the granting of stock options to 5 new employees as part of their inducement awards. The options allow the purchase of 64,900 shares of common stock at an exercise price of $3.34 per share, matching the company's last reported sale price on April 1, 2025.
The stock options, approved by Olema's Compensation Committee under the 2022 Inducement Plan, feature a four-year vesting schedule: 25% vests on the first anniversary, followed by 36 monthly installments over three years, contingent on continuous employment. The options have a 10-year term and comply with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA) ha annunciato l'assegnazione di opzioni su azioni a 5 nuovi dipendenti come parte dei loro premi di indennizzo. Le opzioni consentono l'acquisto di 64.900 azioni di azioni ordinarie a un prezzo di esercizio di $3,34 per azione, corrispondente all'ultimo prezzo di vendita riportato dall'azienda il 1 aprile 2025.
Le opzioni su azioni, approvate dal Comitato per la Compensazione di Olema nell'ambito del Piano di Indennizzo 2022, prevedono un programma di maturazione di quattro anni: il 25% matura al primo anniversario, seguito da 36 rate mensili nell'arco di tre anni, a condizione di un impiego continuativo. Le opzioni hanno un termine di 10 anni e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA) ha anunciado la concesión de opciones sobre acciones a 5 nuevos empleados como parte de sus premios de inducción. Las opciones permiten la compra de 64,900 acciones de acciones ordinarias a un precio de ejercicio de $3.34 por acción, coincidiendo con el último precio de venta informado por la empresa el 1 de abril de 2025.
Las opciones sobre acciones, aprobadas por el Comité de Compensación de Olema bajo el Plan de Inducción 2022, cuentan con un programa de adquisición de cuatro años: el 25% se adquiere en el primer aniversario, seguido de 36 cuotas mensuales durante tres años, condicionado a la continuidad del empleo. Las opciones tienen un plazo de 10 años y cumplen con la Regla de Cotización Nasdaq 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA)는 5명의 새로운 직원에게 유도 보상의 일환으로 주식 옵션을 부여했다고 발표했습니다. 이 옵션은 64,900주의 보통주를 주당 $3.34의 행사 가격으로 구매할 수 있게 하며, 이는 2025년 4월 1일 회사가 보고한 마지막 판매 가격과 일치합니다.
이 주식 옵션은 Olema의 보상 위원회에 의해 2022 유도 계획에 따라 승인되었으며, 4년의 분할 일정을 특징으로 합니다: 첫 번째 기념일에 25%가 분할되고, 이후 3년 동안 매달 36회 분할 지급됩니다. 이는 지속적인 고용을 조건으로 합니다. 이 옵션은 10년의 유효 기간을 가지며 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
Olema Pharmaceuticals (Nasdaq: OLMA) a annoncé l'octroi d'options d'achat d'actions à 5 nouveaux employés dans le cadre de leurs récompenses d'incitation. Les options permettent l'achat de 64 900 actions ordinaires à un prix d'exercice de 3,34 $ par action, correspondant au dernier prix de vente rapporté de l'entreprise le 1er avril 2025.
Les options d'achat d'actions, approuvées par le Comité de Rémunération d'Olema dans le cadre du Plan d'Incitation 2022, présentent un calendrier d'acquisition de quatre ans : 25 % sont acquises à la première anniversaire, suivi de 36 versements mensuels sur trois ans, sous réserve d'un emploi continu. Les options ont une durée de 10 ans et sont conformes à la règle de cotation Nasdaq 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA) hat die Gewährung von Aktienoptionen an 5 neue Mitarbeiter im Rahmen ihrer Anreizprämien bekannt gegeben. Die Optionen ermöglichen den Kauf von 64.900 Aktien zu einem Ausübungspreis von 3,34 $ pro Aktie, der dem zuletzt am 1. April 2025 gemeldeten Verkaufspreis des Unternehmens entspricht.
Die von Olemas Vergütungsausschuss im Rahmen des Anreizplans 2022 genehmigten Aktienoptionen sehen einen vierjährigen Vesting-Zeitplan vor: 25% werden am ersten Jahrestag fällig, gefolgt von 36 monatlichen Raten über drei Jahre, abhängig von einer kontinuierlichen Beschäftigung. Die Optionen haben eine Laufzeit von 10 Jahren und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- Company demonstrates ability to attract new talent with equity compensation
- Stock options align new employee interests with shareholder value
- Potential future dilution from 64,900 new shares
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 5 new employees to purchase an aggregate of 64,900 shares of the Company's common stock, effective as of April 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What are the terms of OLMA's April 2025 employee stock options grant?
How many new employees received stock options from OLMA in April 2025?
What is the exercise price for OLMA's April 2025 inducement stock options?
What is the vesting schedule for OLMA's April 2025 inducement grants?
